Terbium radionuclides for theranostic applications in nuclear medicine: from atom to bedside

Camille Van Laere, Michel Koole, Christophe M. Deroose, Michiel Van de Voorde, Kristof Baete, Thomas Elias Cocolios, Charlotte Duchemin, Maarten Ooms, Frederik Cleeren

Research outputpeer-review

Abstract

Terbium features four clinically interesting radionuclides for application in nuclear medicine: terbium-149, terbium-152, terbium-155, and terbium-161. Their identical chemical properties enable the synthesis of radiopharmaceuticals with the same pharmacokinetic character, while their distinctive decay characteristics make them valuable for both imaging and therapeutic applications. In particular, terbium-152 and terbium-155 are useful candidates for positron emission tomography (PET) and single photon emission computed tomography (SPECT) imaging, respectively; whereas terbium-149 and terbium-161 find application in α- and β--/Auger electron therapy, respectively. This unique characteristic makes the terbium family ideal for the “matched-pair” principle of theranostics. In this review, the advantages and challenges of terbium-based radiopharmaceuticals are discussed, covering the entire chain from radionuclide production to bedside administration. It elaborates on the fundamental properties of terbium, the production routes of the four interesting radionuclides and gives an overview of the available bifunctional chelators. Finally, we discuss the preclinical and clinical studies as well as the prospects of this promising development in nuclear medicine.
Original languageEnglish
Pages (from-to)1720-1743
Number of pages24
JournalTheranostics
Volume14
Issue number4
DOIs
StatePublished - 17 Feb 2024

ASJC Scopus subject areas

  • Pharmacology, Toxicology and Pharmaceutics (miscellaneous)
  • Medicine (miscellaneous)

Cite this